Adcendo, a clinical-stage biotech company pioneering the development of first and best-in-class ADCs for cancers with a high unmet medical need, today announced that management will participate in five upcoming investor conferences in September:
https://mma.prnewswire.com/media/2758713/Adcendo_Logo.jpg
— Citi 2025 Biopharma Back-to-School ConferenceFormat: 1×1 meetingsDate: Tuesday, September 2, 2025Location: Boston, MA
— Wells Fargo 2025 Healthcare ConferenceFormat: Company presentationDate: Wednesday, September 3, 2025Time: 3:45 p.m. ETLocation: Boston, MA
— Cantor Global Healthcare ConferenceFormat: 1×1 meetingsDate: Thursday, September 4, 2025Location: New York, NY
— Morgan Stanley 23rd Annual Global Healthcare ConferenceFormat: Company presentationDate: Monday, September 8, 2025Time: 1:50 p.m. ETLocation: New York, NY
— Bank of America Healthcare Trailblazers Private Company ConferenceFormat: 1×1 meetingsDate: Wednesday, September 17, 2025Location: Boston, MA
About Adcendo
Adcendo is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts. The company is developing a pipeline of first-in-class antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs. Led by a team of industry veterans with a track record of advancing multiple ADCs to approval, Adcendo integrates novel targets, optimized linker-payload combinations, and a rationally designed development strategy to drive next-generation cancer therapies. For further information, please visitwww.adcendo.comor follow the company onLinkedIn.
https://c212.net/c/img/favicon.png?sn=NY59756&sd=2025-08-27
View original content to download multimedia:https://www.prnewswire.com/news-releases/adcendo-aps-to-participate-in-upcoming-september-investor-conferences-302539566.html
SOURCE Adcendo
https://rt.newswire.ca/rt.gif?NewsItemId=NY59756&Transmission_Id=202508270700PR_NEWS_USPR_____NY59756&DateId=20250827